Menu Search
Equities

Biotage AB

BIOT:STO

Biotage AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)155.00
  • Today's Change3.90 / 2.58%
  • Shares traded38.87k
  • 1 Year change+22.72%
  • Beta1.2888
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in SEK

The 4 analysts offering 12 month price targets for Biotage AB have a median target of 206.00, with a high estimate of 275.00 and a low estimate of 196.00. The median estimate represents a 32.90% increase from the last price of 155.00.
High77.4%275.00
Med32.9%206.00
Low26.5%196.00

Dividends

In 2023, Biotage AB reported a dividend of 1.60 SEK, equaling last years dividend. The 3 analysts covering the company expect dividends of 1.69 SEK for the upcoming fiscal year, an increase of 5.44%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in SEK

On Oct 23, 2024, Biotage AB reported 3rd quarter 2024 earnings of 0.55 per share.
The next earnings announcement is expected on Feb 19, 2025.
Average growth rate+50.45%
Biotage AB reported annual 2023 earnings of 3.33 per share on Feb 15, 2024.
Average growth rate+13.34%
More ▼

Revenue history & estimates in SEK

Biotage AB had 3rd quarter 2024 revenues of 490.00m. This missed the 505.80m consensus estimate of the 2 analysts following the company. This was 35.73% above the prior year's 3rd quarter results.
Average growth rate+5.02%
Biotage AB had revenues for the full year 2023 of 1.86bn. This was 18.90% above the prior year's results.
Average growth rate+19.70%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.